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Motor neuron loss is characteristic of many neurodegenerative disorders and results in rapid loss of muscle control, paralysis, and
eventual death in severe cases. In order to investigate the neurotrophic effects of a motor neuron lineage graft, we transplanted
human embryonic stem cell-derived motor neuron progenitors (hMNPs) and examined their histopathological effect in three
animal models of motor neuron loss. Specifically, we transplanted hMNPs into rodent models of SMA (Δ7SMN), ALS (SOD1
G93A), and spinal cord injury (SCI). The transplanted cells survived and differentiated in all models. In addition, we have also
found that hMNPs secrete physiologically active growth factors in vivo, including NGF and NT-3, which significantly enhanced
the number of spared endogenous neurons in all three animal models. The ability to maintain dying motor neurons by delivering
motor neuron-specific neurotrophic support represents a powerful treatment strategy for diseases characterized by motor neuron
loss.
1. Introduction
Human embryonic stem cells (hESCs) can differentiate into
any cell type, are amenable to genetic manipulation, and
readily self-renew in vitro. Directed differentiation of hESCs
into high purity populations of a defined cell type can be
used to design effective treatments that are both cell and
site specific. Stem cell-based transplantation is an inherently
combinatorial therapeutic approach, in that it not only
replaces dead or dying cells, but also provides a substrate
for endogenous growth, bridges gaps where tissue is lost to
injury or disease, and provides neurotrophic support for the
endogenous environment.
Amyotrophic lateral sclerosis (ALS), spinal muscular
atrophy (SMA), and spinal cord injury (SCI) are all diseases
of motor neuron loss that could potentially benefit from
transplantation of hESC-derived cells. ALS is the most
common form of motor neuron disease [1] and can be either
sporadic or familial [2–5]. Approximately 5–10% of those
diagnosed have a positive family history of the disease [1, 6].
Although the etiology of the sporadic form of ALS is largely
unknown [5], the familial form has a strong genetic linkage
to point mutations in either TAR DNA-binding protein 43
(TDP-43), FUS/TLS, or the Cu/Zn superoxide dismutase 1
(SOD1) genes [7]. The average age of onset is between 40 and
60 years, and the disease is generally fatal within 1–5 years
of onset [1, 6]. SMA is also characterized by motor neuron
loss and is the leading genetic cause of infantile death [8, 9].
The disease manifests by roughly 6 months of age in the most
severe cases (type I), and death follows in ∼2 years without
supporting intervention [9, 10]. It is caused by a deletion
or mutation in the Survival Motor Neuron (SMN1) gene
[9, 11] in approximately 1 of every 10,000 live births [9, 10].
SCI involves several degenerative processes including but not
limited to axonal and cellular damage to the motor neuron
compartment [12]. Each of these three neurodegenerative
diseases is characterized by the progressive loss of muscle
control and death of motor neurons within the spinal cord.
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Because the adult central nervous system (CNS) has a limited
ability to repair itself, therapeutic strategies have focused
on ameliorating secondary cellular degeneration [12, 13],
promoting endogenous repair mechanisms [14–16], and cell
replacement [12, 17–19].
There is much evidence that transplantation of stem and
progenitor cells into the CNS produces functional improve-
ment even in the absence of functional integration. Human
neural stem cells constitutively secrete the neurotrophins
NGF, BDNF, and GDNF that promote growth of injured
axons following spinal cord injury [14, 20]. At least a portion
of the functional recovery seen after transplantation of
hESC-derived oligodendrocyte progenitor cells into models
of SCI has been attributed to secretion of growth factors
by the transplanted cells [12, 20–22]. This data indicates
that growth factors secreted by transplanted stem cells can
significantly influence pathogenesis of the diseased/injured
spinal cord [20].
We have previously documented a method to differenti-
ate hESCs into high purity populations of human embryonic
stem cell-derived motor neuron progenitors (hMNPs) [20].
In this study, we sought to investigate whether hMNPs secrete
growth factors that have neurotrophic effects on neurons
in culture and in three different models of motor neuron
loss. We demonstrate that hMNPs secreted physiologically
active growth factors in vitro and in vivo and significantly
enhanced the number of endogenous neurons following
transplantation in all three animal models of motor neuron
loss. From a therapeutic perspective, these observations
indicate that cell transplantation benefits pathogenesis by
growth factor secretion, in addition to cell replacement.
2. Materials and Methods
2.1. Ethics Statement. All animal work was carried out in
accordance with the UCI Institutional Animal Care and
Use Committee (2007-2725). Animals received appropriate
postsurgical care including subcutaneous saline, prophylactic
Baytril (2.5mg/kg/d, s.c.; Bayer, Shawnee Mission, KS),
and Buprenorphine (0.025mg/kg/d, s.c.; Western Medical
Supply, Los Angeles, CA) for three days. Animals were
inspected for weight loss, dehydration, discomfort, and
autophagia, with appropriate veterinary care as needed.
Research involving human participants was approved by the
UCI Institutional Review Board (2008-6467) and the UCI
Medical Center with written informed consent. All work
involving human embryonic stem cells was approved by the
UCI Human Embryonic Stem Cell Research and Oversight
Committee (2007-5645).
2.2. Derivation of hMNPs from hESCs. hMNPs were derived
from hESC lines hCSC14, hCSC14-CL1 (California Stem
Cell, Inc., Irvine, CA) at passages 15–17 and H7 at passages
26–38. hESCs were expanded on Matrigel (BD Biosciences,
San Jose, CA) for 1–3 weeks in StemBlast media (Cal-
ifornia Stem Cell, Inc., Irvine, CA) supplemented with
20 ngbFGF/mL (Millipore, Billerica, MA). Cells were then
transferred to ultra low-binding dishes (Corning, NY) and
suspended in motor neuron (MN) differentiation media,
which consisted of osmolarity adapted DMEM : F12 mixture
(260mOsm) supplemented with Glutamax, B27 supplement
(Gibco-Invitrogen, Carlsbad, CA), insulin 10 µg/mL, sodium
selenite 1 ng/mL, transferrin 10 µg/mL (Sigma Aldrich, St.
Louis, MO), MgSO4 0.5Mm, and bFGF 5 ng/mL (Millipore,
Billerica, MA). Cells were exposed to this media for 5 days,
supplemented with 10 µM retinoic acid (RA; from 20mM
stock solution in DMSO, Sigma-Aldrich, St. Louis, MO).
Cultures were fed daily for the duration of RA treatment,
then every 2 days for 16 subsequent days. At day 21,
cell clusters were transferred to adherent laminin substrate
(20 µg/cm2). At day 28, the conditioned media was collected
for in vitro assays, or the cells were prepared for transplanta-
tion. Subsets of cells were plated onto laminin coated 4-well
chamber slides (Nunc; Fisher Scientific, Pittsburgh, PA) for
immunocytochemical profiling.
2.3. Preparation of MN-Astrocyte Cocultures. To assess matu-
ration into a motor neuron phenotype, hMNPs were plated
onto primary astrocytes on day 28 and allowed to mature
for 3 weeks thereafter according to previously published
protocols [20] and Dr. John Weiss of UC, Irvine. Briefly,
astrocyte cultures were prepared from cerebral cortices of
early postnatal (1–3 day) mice. After removing cortices,
the tissue was dissociated and plated at a density of about
2 × 104 cells/cm2, in media consisting of Eagle’s minimal
essential medium (MEM, Earle’s salts, supplied glutamine
free; serum; Gibco; Grand Island, NY), supplemented with
10% heat-inactivated horse serum (Gibco), 10% fetal bovine
serum (Gibco), glutamine (2mM; Gibco), glucose (total
25mM), and epidermal growth factor (final concentration
10 ng/mL) in 15mm Primaria-coated culture plates (Falcon;
Franklin Lake, NJ). Cultures were maintained in a 37◦C/5%
CO2 incubator. Under these conditions, there is virtually
no neuronal survival, the astrocyte monolayers generally
become confluent after ∼2 weeks. After confluence, the
astrocytemonolayers were seeded with hMNP sat a density of
50,000 cells/cm2. Subsequently, media was exchanged twice
a week. Mature motor neurons were immunostained and
characterized as below.
2.4. Immunocytochemical Labeling. Immunocytochemistry
was performed using standard protocols, as described
previously [20]. The following proteins were evaluated:
anti-TUJ1 (1 : 1000), anti-HB9 (1 : 100; MNR2 Ab from
DSHB Developmental Studies Hybridoma Bank), anti-Islet1
(1 : 200), anti-GFAP (1 : 500) anti-SMI32 (1 : 1000), and anti-
ChAT (1 : 100;Millipore at 4◦C overnight). Primary antibody
application was followed by fluorescent secondary antibody
application (Alexafluor-488 or -594 conjugated; Invitrogen,
Carlsbad, CA).
2.5. Primary Cortical Cultures. Mixed primary cortical
cultures were prepared from postnatal day 1 Sprague-
Dawley rats for neurite outgrowth with and without hMNP-
conditioned media (CM) or MN differentiation media
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(without conditioning) as previously described in Rossi et
al. [20]. Briefly, the cortex was mechanically dissociated,
trypsinized, and spun at 1500 g for 5 minutes. The pellet
was resuspended in Neurobasal media (Invitrogen, Carlsbad,
CA). 40,000 cells were plated onto poly-L-lysine coated
chamber slides for neurite outgrowth [23]. After seeding, the
chamber slides were fed for the next 2 days with Neurobasal
media supplemented with 10 ng/mL FGF until neuronal
attachment.
2.6. In Vitro Growth Factor Secretion Assay. To determine
whether hMNP-conditioned media had neurotrophic effects
on neurite outgrowth, MN differentiation media was condi-
tioned for 48 hours in the presence of hMNPs and removed
for presentation to cortical neurons. Primary cortical neu-
rons were fed with either MN differentiation media or
hMNP-CM diluted 1 : 1 withMN differentiationmedia (n =
4/group). MN differentiation media (without condition-
ing) consisted of osmolarity adapted DMEM : F12 mixture
(260mOsm) supplemented with Glutamax, B27 supple-
ment (Gibco-Invitrogen, Carlsbad, CA), insulin 10mg/mL,
sodium selenite 1 ng/mL, transferrin 10mg/mL (Sigma
Aldrich, St. Louis, MO), MgSO4 0.5mM, and bFGF 5ng/ml
(Millipore, Billerica, MA) [20].
2.7. Transplantation of hMNPs ALS Model. The SOD1 G93A
mutant mice were supplied and bred for ALS-TDI by
GTC Biotherapeutics. Immune suppression was initiated
48 hours before procedures and consisted of a mixture of
FK506/Rapamycin, 1mg/kg of each. A laminectomy was
performed at lumbar level L2 across two vertebral bodies
at 60 days old. For transplantation, 32G Hamilton needles
with 30◦ bevels were used. A total of 40,000 hMNPs or CTS
(vehicle) were injected intraspinally. Each injection was a
total volume of 1 µL, at a dose of 10,000 cells/µL/injection.
Animals were survived to 110 days old.
Mice were divided into two groups of treated (transplan-
tation with hMNPs; n = 25) and vehicle control (vehicle-
injected; n = 25) groups that were evaluated up to the
end stage for protein expression and histological evaluation
of donor cell phenotype. Furthermore, 1 group of animals
(composed of 15 mice for both hMNP treated and vehicle
control SOD1 G93A mice) were analyzed for histological
quantification and 1 group of animals were analyzed for
molecular analysis (composed of 10 mice for both hMNP
treated and vehicle control SOD1 G93A mice).
SMA Model. At postnatal day 1, Smn−/−; SMNΔ7+/+;
SMN2+/+ (hereafter referred to as Δ7SMN) pups were
cryoanesthetized, and a laminectomy was performed in the
upper lumber region. A glass-pulled tip attached to a Hamil-
ton syringe was secured to a stereotactic apparatus and a total
of 20,000 hMNPs (10,000 cell/uL) or volume equivalent of
vehicle was transplanted bilaterally into the spinal cord [24].
Mice were divided into treated (transplantation with hMNPs;
n = 11) and vehicle control (vehicle-injected; n = 4) groups
that were evaluated up to the end stage for histological
analysis. Animals were survived up to 14 days old following
transplant.
SCI Model. Adult, female Sprague-Dawley rats (Charles
River Laboratories, San Diego, CA) were anesthetized using
Ketamine (100mg/kg) and Xylazine (10mg/kg, i.p.: West-
ern Medical Supply, Los Angeles, CA) and underwent a
T3 laminectomy. A 200 kD bilateral contusion injury was
delivered using an Infinite Horizons Impactor (Precision
Systems and Instruments, Lexington, KY). Animals received
a solution of 5mL ringers, 0.02mL Baytril, and 0.4mL
diluted buprenorphine subcutaneously 2 days postinjury.
Animals were also bladder expressed twice a day for min-
imum of 3 days, then as needed. Twenty-four hours prior
to transplantation, animals began daily immunosuppression
with cyclosporine A (20mg/kg/d, s.c.; Bedford Laboratories,
Bedford, OH). Animals also received antibiotic treatment of
Baytril (0.02mL) beginning one day prior to transplantation
and continued throughout post-op. Seven days after spinal
cord injury, animals received a transplantation of hMNPs;
following reexposure of the laminectomy site, the spinal
process of T2 was immobilized, and a 10 µLHamilton syringe
(Hamilton, Reno, NV) with a 33G beveled needle was
lowered into the spinal cord using a stereotactic manipulator
arm. A total of 100,000 hMNPs or CTS (vehicle) was injected
in a total of four sites, 2 bilateral injections cranial and caudal
to the injury site (0.5mm lateral, 1.2mm deep) to target the
ventral horn. Each injection consisted of a total volume of
1 µL, at a dose of 25,000 cells/µL [20].
Mice were divided into two groups of treated (transplan-
tation with hMNPs; n = 30) and vehicle control (vehicle-
injected; n = 30) groups that were evaluated up to the end
stage for protein expression and histological evaluation of
donor cell phenotype. Furthermore, animals were split into
2 groups; the first group was (composed of 20 mice for both
hMNP-treated and vehicle control SCI mice) analyzed for
histological quantification and the second group of animals
was analyzed for molecular analysis (composed of n =
10 mice for both hMNP-treated and vehicle control SCI
mice). Animals were survived up to 3 months following
transplant.
2.8. Immunohistochemical Analyses of hMNPs. Animals were
sacrificed via transcardiac perfusion with 4% paraformalde-
hyde. The tissue was cryopreserved in 27% sucrose, and the
cords were sectioned into 1mm blocks and embedded in
OCT compound. Tissue was cryosectioned at 20 µm and
mounted onto gelatin-coated slides. Tissue sections were
blocked with 10% NDS in PBS and permeabilized with 0.1%
Triton X-100. To determine the fate of the transplanted
hMNPs, sections were processed for multiple markers.
Primary antibodies were added overnight at 4◦C for Ku80
(1 : 300; Abcam), Islet-1 (1 : 200; Abcam), biotinylated NeuN
(1 : 200; Millipore), p75 (1 : 200, Santa Cruz Biotechnology,
Santa Cruz, CA), and ChAT (1 : 100; Millipore). Donkey
antirabbit conjugated with biotin (1 : 250; Invitrogen), Strep-
tavidin 594 (1 : 250; Invitrogen), Streptavidin 488 (1 : 250;
Invitrogen), or goat antirabbit Alexa Fluor-488/-594 (1 : 250;
Invitrogen) was used for 2 hours at room temperature as
secondary antibodies.
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2.9. Neuronal Sparing Analysis. The spinal cords from all
three animal models were analyzed for neuronal sparing.
Every tenth slide, spaced 200 µm apart, was processed in
order to visualize the length of the spinal cord [20]. IHC
staining was performed on tissue slides using mouse anti-
NeuN (1 : 200; Millipore) primary antibodies to identify
neurons and rabbit anti-Ku80 (1 : 300; Abcam) primary anti-
bodies to identify human nuclei. Serial sections were labeled
with human nuclear antigen to ensure no human cells were
included in the analysis. For motor neuron sparing analysis,
mouse anti-ChAT (1 : 100; Millipore) primary antibodies
and rabbit anti-Ku80 (1 : 300; Abcam) primary antibodies
were used. The antibodies were diluted in PBS, incubated
overnight at 4◦C. Vector ABC Biotin Kit and Vectastain
DAB Substrate Kits were used for secondary detection.
Hoechst was used as a nuclear counterstain. Following IHC
staining, the tissue was imaged using an Olympus AX-80
microscope. Images were taken of transverse sections of
the ventral horns using MicroFire software. NeuN-positive
neurons were quantified up to 2mm cranial and 2mm
caudal to the injury epicenter or transplant site. The number
of neurons was quantified using ImageJ software. Each image
was opened individually and changed to an 8-bit image. Each
image was then inverted, then the brightness and contrast
was adjusted to the Auto setting, which made the gray areas
darker and neurons were more easily visible. Then, threshold
was adjusted from Default to MaxEntropy setting. Finally,
the Nucleus Counter plug-in was used to detect pixels, the
smallest particle size set to 400 and largest particle size set
to 2000. Background subtraction and watershed filter were
used in the plug-in. The plug-in then showed the black and
white image of the neurons with a number indicating that
it was counted and a summary table of the total counts. If a
cell double stained positive for both NeuN and Ku80, then
that cell was not used in quantification. Statistical analysis
was performed using a Student’s t-test (2 tailed distribution
and two sample equal variance).
2.10. ELISA. Transplanted spinal cords were analyzed for
growth factor expression using ELISA. Fresh epicenter blocks
were flash frozen and then homogenized. Samples were
homogenized in ice cold T-Per Protein Extraction Reagent
(Pierce Biotechnology, Rockford, IL). Samples were kept at
−20◦C until analyzed with BCA protein assay. Triplicate
supernatant samples were used to determine total protein
levels present within the tissue using a BCA protein assay
kit (Pierce, Rockford, IL). Optical densities were read on
a THERMOmax ROM v1.72 plate reader at 450 nm, and
the respective protein levels were quantified in comparison
to a bovine serum albumin (BSA) standard curve. The
ELISA kits used were NT-3 Emax Immuno Assay System
(Promega), NGF Emax ImmunoAssay System (Promega),
VEGF human ELISA kit (Invitrogen), NT-4 AccuBind ELISA
kit (MonoBind, Inc.).
3. Results
3.1. In Vitro Differentiation. At day 28, the day of trans-
plantation, 93 ± 2.3% of cells expressed the neuronal axon
marker TUJ1 (Figure 1(a)), 96 ± 1.7% of the cells expressed
the motor neuron marker Islet-1 (Figure 1(b)), and 97 ±
2.6% of cells expressed the motor neuron marker HB9
(Figures 1(c) and 1(d)). Less than 1% of cells expressed the
astrocyte marker GFAP (Figure 1(a)) and no cells expressed
the mature motor neuron marker ChAT at day 28. No Oct4
positive stem cells could be identified on or after day 28 of
the differentiation protocol.
To assess maturation in vitro, hMNPs were plated
on astrocytes and allowed to mature for a subsequent
3 weeks following day 28 of the differentiation protocol
(Figures 1(e) and 1(f)). Astrocytes did not immunostain
for the motor neuron markers SMI-32 (Figure 1(e)) and
ChAT (Figure 1(f)), but were evident by hoescht staining.
Quantification of astrocyte positive cells was therefore not
performed. The neurofilament marker SMI-32 (Figure 1(e))
was expressed by 97.7 ± 1.53% of the cells and 96.6 ± 4.4%
of the cells expressed themature motor neuronmarker ChAT
(Figure 1(f)); while HB9 expression decreased significantly
(P < .001; 6 ± 4.4%) from the day 28 differentiation
profile. Motor neuron maturation was further demonstrated
by kainate-stimulated uptake of Co2+ ions by Ca2+ permeable
AMPA channels (not shown).
3.2. In Vivo Differentiation. Human nuclear (Ku80) antigen-
positive cells were detected in all transplanted animals of all
3 animal models and did not migrate from the transplant
sites cranial and caudal to the injection sites (Figure (2)).
Human cells (Figures 2(a) and 2(c)) double stained with
the young motor neuron marker Islet-1 (Figure 2(b)) and
were observed in the ventral horns of hMNP treated but
not in vehicle control Δ7SMN animals. In Δ7SMN animals,
human nuclear antigen-positive cells did not double label
with markers for the mature motor neuron markers ChAT or
SMI-32, indicating that their limited time in vivo (13 days)
is insufficient for differentiation of transplanted hMNPs.
However, human cells were found within the SOD1 G93A
and SCI animals, in which animals were survived for up to
2 and 3 months, respectively, after transplantation. Human
cells were colabeled with neuronal and motor neuron
markers such as NeuN (Figure 2(d)), p75 (Figure 2(e)) and
ChAT (Figure 2(f)), consistent with a motor neuron lineage
of a mixed maturation state. Many human nuclear antigen-
positive cells extended TUJ1-positive processes. TUJ1 tissue
staining was absent in no-primary and no-secondary anti-
body controls. Transplanted cells did not extend axons into
the periphery or form neuromuscular junctions with host
tissue, as expected.
3.3. In Vitro Growth Factor Secretion. Rossi et al [20]
have previously shown that hMNP’s secrete various growth
factors. To investigate the neurotrophic potential of hMNP
secretions, we performed functional assays of hMNP secre-
tions on cortical neurons in vitro (Figure 3). Neurite length
of cortical neuron cultures exposed to hMNP-conditioned
media (Figure 3(a)) was compared to neurite length of cor-
tical neuron cultures exposed to control MN differentiation
media only (without conditioning) (Figure 3(b)) and was
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TUJ1 GFAP
(a)
ISLET-1 TUJ1
(b)
HB9
(c)
HB9 TUJ1
(d)
SMI32
(e)
ChAT
(f)
Figure 1: hMNP differentiation in vitro. At day 28, GFAP+ astrocytes ((a) red) were rare within TUJ1+ ((a) green) cultures. The majority
of TUJ1+ cells ((b, d) red) double stained for the motor neuron lineage marker Islet-1 ((b) green) and HB9 ((c, d) green). After 3 weeks of
subsequent growth, cells displayed a mature, branched morphology consistent with mature motor neurons, and expressed the mature motor
neuron markers SMI-32 ((e) green) and ChAT ((f) green). Counterstain in blue (a, d, e) and red (f). Bar = 50 µm.
found to be significantly greater (P < .05; (Figure 3(c)).
Neurite length of cortical neuron cultures exposed to hMNP-
conditioned media was 250µm ± 27µm, and neurite length
of cortical neuron cultures exposed to MN differentiation
media only was 151µm ± 32µm.
3.4. In Vivo Growth Factor Secretion. The presence of growth
factors NGF, NT-3, VEGF, and NT-4, in the spinal cord of
animals was assessed in whole protein extracts via ELISA
(Figure 4). The levels of NGF protein were significantly
greater (P < .05) in hMNP-transplanted animals (76.3 ±
3.0 pg/mL) as compared to vehicle control animals (68.1 ±
2.0 pg/mL; Figure 4(a)). Similarly, the levels of NT-3 protein
were significantly greater (P < .05) in hMNP-transplanted
animals (66.5 ± 7.2 pg/mL) as compared to vehicle control
animals (50.5 ± 3.1 pg/mL; Figure 4(b)). There was no
significant difference (P > .05) in the level of VEGF
between the vehicle control (387.8± 13.3 pg/mL) and hMNP
transplanted animals (382.9 ± 13.9 pg/mL; Figure 4(c)).
Interestingly, NT-4 levels were significantly greater (P <
.01) in the vehicle control animals (98.0 ± 4.5 µg/mL), as
compared to hMNP-transplanted animals (79.3± 3.4 µg/mL;
Figure 4(d)).
3.5. Neuronal Sparing. The average number of neurons in
the hMNP treated group and vehicle control group of all
6 Stem Cells International
Ku80
(a)
Ku80 ISLET-1
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ChAT
(f)
Figure 2: hMNP differentiation in vivo. Human nuclear (Ku80) antigen-positive cells were detected in all treated animals of all 3 animal
models and colabeled with different motor neuron differentiationmarkers.Human nuclear (Ku80) antigen-positive cells (a, c) double stained
with Islet-1 ((b) red), NeuN ((d) NeuN in red, human nuclei in green), p75 ((e) p75 in red, human nuclei in green), or ChAT ((f) ChAT in
blue, human nuclei in brown), consistent with a motor neuron lineage of mixed maturation state. Bar = 50 µm.
3 animals was assessed for endogenous neuronal sparing
(Figure 5). In SCI and SOD1 G93A hMNP-treated animals
cranial to the injury/injection epicenter, there were 38 ± 3
and 43 ± 5 endogenous neurons counted, respectively. The
average number of neurons in the vehicle control group
of SCI and SOD1 G93A animals cranial to injury/injection
epicenter was 29 ± 2 and 27 ± 3, respectively. Cranial to the
injury/injection epicenter, the hMNP-treated group showed
a significant sparing of neurons compared to the vehicle
control group in SCI (Figure 5(a); P < .01) and SOD1
G93A animals (Figure 5(c); P < .05). The average number of
neurons in the hMNP-treated group of SCI animals caudal
to the injury/injection epicenter was 36 ± 4. The average
number of neurons in the vehicle control group of SCI
animals caudal to the injury/injection epicenter was 37 ± 3.
The hMNP-treated group did not demonstrate statistical sig-
nificance in neuronal sparing in SCI or SOD1 G93A animals
caudal to the injury/injection epicenter. Therefore, caudal
to the injury/injection epicenter, neuronal sparing was not
affected by the transplantation of hMNPs, whereas hMNP
transplantation (Figure 5(e)) did spare neurons cranial to
the injury/injection epicenter and the vehicle control did not
(Figure 5(f)).
The average number of neurons in the hMNP treated
group in Δ7SMN animals cranial to the injection epicenter
was 304 ± 30. In the vehicle control group, the average
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Figure 3: hMNPs cause neurite branching in vitro. Neurite length was significantly longer (P < .05) in cortical neuron cultures exposed to
hMNP-conditioned media (a) for 7 days as compared to cortical neuron cultures exposed to control MN differentiation media (b). (c) The
length of neurites in cultures exposed to hMNPconditioned media as compared to those exposed to control media was significantly higher
(P < .05). Bar = 50 µm.
number of neurons cranial to injection epicenter was 304
± 46. Cranial to the injection epicenter, the hMNP-treated
group did not demonstrate a significant sparing of neurons
compared to the control group (Figure 5(d)). The average
number of neurons in the hMNP-treated group in Δ7SMN
animals caudal to the injection epicenter was 386 ± 18.
However, average number of neurons in the vehicle control
group caudal to the injection epicenter was 282± 29. Caudal
to the injection epicenter, the hMNP-treated group showed
statistical significance in neuronal sparing (Figure 5(d); P <
.05). Therefore, cranial to the injection epicenter, neuronal
sparing was not affected by the transplantation of hMNPs,
whereas hMNP transplantation did spare neurons caudal to
the injection epicenter.
3.6. Motor Neuron Sparing. The average number of ChAT
positive cells in the hMNP treated and vehicle control groups
was compared to examine whether neuronal sparing may
have included endogenousmotor neurons (Figure 5(b)). The
average number of ChAT-positive cells within the ventral
horn in SCI animals of the hMNP-transplanted group cranial
to the injury/injection epicenter was 12 ± 2. The average
number of ChAT positive cells within the ventral horn
in SCI animals of the vehicle control group cranial to
the injury/injection epicenter was 7 ± 2. The number of
ChATpositive cells cranial to the injury/injection epicenter in
the hMNP treated group was significantly greater (P < .05)
than that of the vehicle control group, demonstrating that
hMNP transplantation resulted also in the specific sparing
of endogenous motor neurons. There was no significant
difference in the number of ChAT positive cells caudal to the
injury/injection epicenter, although there is a trend towards
increased sparing. The number of ChAT-positive cells caudal
to the injury/injection epicenter in the hMNP treated group
was 13 ± 2. The number of ChAT-positive cells caudal to the
injury/injection epicenter in the vehicle control group was 9
± 2.
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Figure 4: hMNPs secrete physiologically active growth factors in vivo. ELISA data of NGF (a), NT-3 (b), VEGF (c), and NT-4 (d) protein
levels in the thoracic spinal cord transplanted region of SCI rats. Data is expressed as mean ± standard error. ∗P < .05; ∗∗P < .01. n = 6
hMNP; n = 9 vehicle.
4. Discussion
Transplantation is an inherently combinatorial therapeutic
approach, as it may provide neurotrophic support for the
endogenous environment, and cell phenotype-related ben-
efits such as replacement of dead or dying cells, a substrate
for endogenous growth, or a tissue bridge for endogenous
growth. The relative contribution of neurotrophic support
and phenotypic benefits conferred by a transplant is difficult
or impossible to discern for transplants that consist of mixed
lineages. In this study, we investigated the neurotrophic
effects of a high purity motor neuron lineage graft in three
animal models of motor neuron loss. We demonstrate that
hMNPs secreted physiologically active growth factors in
vitro and in vivo and significantly enhanced the number
of spared endogenous neurons following transplantation in
three animal models of motor neuron loss. The ability to
maintain dying motor neurons by delivering motor neuron-
specific neurotrophic support represents a powerful treat-
ment strategy for diseases characterized by motor neuron
loss.
Motor neurons respond to neurotrophic cues and express
and secrete various growth factors [25]. Our data indicate
that hMNPs secrete NT-3, and NGF, and our previous
publication further indicates that they secrete VEGF and NT-
4 [20]. NT-3 and VEGF have known beneficial effects onCNS
pathogenesis [16, 26]. Furthermore, our in vitro data demon-
strate that hMNP-conditioned media enhanced elongation
and branching of cortical neurites, demonstrating that the
growth factor secretions from hMNPs were physiologically
relevant.
Our transplantation studies further confirm that hMNPs
have physiologically relevant neurotrophic effects in the
vicinity of the transplant. hMNP transplantation into SMA,
ALS, and SCI animal models resulted in beneficial effects
on injury pathogenesis, as evidenced by a greater num-
ber of spared endogenous neurons in all three animal
models. Although the growth factors secreted by hMNPs
in vivo have been implicated in neuronal survival [16,
26], the mechanisms underlying their interaction with the
endogenous environment are unknown. Their mechanism
of action may be direct, or indirect, as trophic support
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Figure 5: hMNP transplantation spares endogenous neurons. (a) Comparison of NeuN positive cells in cranial (n = 13 hMNP; n = 15
vehicle) and caudal (n = 14 hMNP; n = 15 vehicle) transverse sections in SCI animals. (b) Comparison of ChAT positive cells in cranial
(n = 10 hMNP; n = 12 vehicle) and caudal (n = 9 hMNP; n = 12 vehicle) transverse sections of ventral horns in SCI animals. (c)
Comparison of NeuN positive cells in cranial transverse sections of SOD1 G93A animals (n = 5 hMNP; n = 5 vehicle). (d) Comparison
of NeuN positive cells in cranial (n = 3 hMNP; n = 3 vehicle) and caudal (n = 3 hMNP; n = 2 vehicle) transverse sections of Δ7SMN
animals. NeuN stained histological sections of lumbar spinal cord from hMNP (e) and vehicle (f) injected into SOD1 G93A mice clearly
show a difference in neuronal numbers. Data is expressed as mean ± standard error. ∗P < .05. Bar = 50 µm.
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of glial cells and/or modulation of the immune or glial
response may have contributed to survival of endogenous
neurons. Neurons within regions of pathology upregulate
p75 neurotrophin receptors (p75NTR) and downregulate
tyrosine-related kinase receptors (TrkRs) [16, 26]. The
p75NTR binds the precursor forms of neurotrophins and has
been implicated in apoptosis, while TrkRs bindmature forms
of neurotrophins and have been implicated in beneficial
neurotrophic effects [16, 26]. hMNP-secreted growth factors
may prevent, inhibit, or counteract neurotrophic action at
the p75NTR and/or enhance activation and/or upregulation
of TrkRs, enhancing downstream neurotrophic effects.
This study directly assessed the potential of a cell-based
therapeutic to confer neurotrophic benefit to regions of
pathogenesis in the absence of phenotypic benefit. hMNP
transplants did not extend processes to reinnervate distant
muscles, so their neurotrophic benefit to the diseased or
injured spinal cord could be investigated in isolation from
phenotypic benefits conferred by a transplant. These findings
further our understanding of the neurotrophic benefits
of hMNP transplantation. Nonetheless, efforts to mature
transplanted hMNPs and enhance axonal projection to target
muscles are important to maximize the benefits of this cell
population.
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